Project Grant R56AR083234
Award Date
9/18/23
Completion Date
8/31/24
Dollars Obligated
$239K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded a $383,570 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Trustees of Indiana University, doing business as Indiana University Indianapolis. The grant, titled "Delineating the Contribution of Muscle Wasting to Tumor Progression," aims to better understand the relationship between skeletal muscle wasting and tumor progression in cancer patients. The...
This $146,816 Project Grant was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant, running from July 1, 2025 to June 30, 2028, will support research to investigate the role of the muscle circadian clock in cancer cachexia, a debilitating condition affecting up to 80% of cancer patients. The research aims to define how disruptions in the muscle clock...
This Project Grant award of $248,724.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of cellular senescence in skeletal muscle loss and dysfunction. The primary objectives are to: 1) obtain experimental skills and career training to develop a translational research program on mechanisms underlying skeletal muscle wasting,...
This federal Project Grant award, R01AR084282, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $458,907 award will fund research to determine if the gut microbiome can be leveraged as a novel therapeutic strategy to treat skeletal muscle atrophy. The key products and services to be delivered include: 1) Evaluating if cecal microbial transplant from...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $526,174 to Duke University to engineer heterocellular human skeletal muscle tissues. The goal is to recreate and study the native stem cell niche function of healthy skeletal muscle, which is critical for its regenerative capacity. By incorporating capillary networks and functional...
This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports a research project titled "Epigenetic Regulation of KLF4 in SSC-Associated Lung Fibrosis" at the Medical University of South Carolina (MUSC). The $119,986 award, effective May 15, 2024 through April 30, 2029, aims to investigate the epigenetic factors regulating the...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research (CFDA 93.396) program, provides $1,396,152.00 in funding to the University of Chicago over the period of December 5, 2024 to November 30, 2029. The research aims to examine the role of the BNIP3 protein and mitophagy (selective autophagy of mitochondria) in muscle atrophy during cancer cachexia, which is common in pancreatic ductal adenocarcinoma (PDAC). Using genetically engineered mouse...
This Project Grant award of $215,600 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research at Baylor University to investigate the use of senolytic compounds to enhance the response to exercise in mice with cancer cachexia. The key objectives are to: 1) Determine if eliminating senescent cells can mitigate cisplatin-induced muscle atrophy, 2) Examine...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a 5-year, $732,272 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the Trustees of Indiana University (Indiana University Indianapolis) to establish the Indiana Center for Musculoskeletal Health (ICMH) Resource Cores. The goal is to promote advancements in musculoskeletal research through understanding muscle/bone interactions, mechanobiology, and the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $151,578 to support research on skeletal muscle loss (sarcopenia) in patients with chronic obstructive pulmonary disease (COPD). The research aims to determine the role of hypoxia-inducible factor 1-alpha (HIF1A) in regulating skeletal muscle protein synthesis and homeostasis in response to prolonged intermittent hypoxia, a condition...